Recent Updates
Recently added Catalysts

RYZ101

Phase 3

GEP-NET | Small Molecules | Oncology |Bristol-Myers Squibb Company|Trials Updated: Nov 12, 2026

RYZ101 development status

Highest phase Phase 3
Registered trials 2 across 1 sponsor since Jul 2022

RYZ101 target and mechanism

ModalitySmall Molecules

Also known as RYZ101 Dose Level 1

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials3
Total Enrollment428

FDA Designations

ORPHAN_DRUG

RYZ101 clinical trials

RYZ101 · 3 trials · 18 indications

Phase 3 1Phase 1/2 1Phase 1 1
NCT05477576Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyGEP-NET
ACTIVE NOT_RECRUITING343 Analytics
PHASE3ACTIVE NOT_RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
GEP-NETUnlock trial analytics

Study Endpoints

Primary Endpoints

Phase 1b: RP3D
56 days of study treatment

Incidence of DLTs during the first 56 days of study treatment will be assessed.

Phase 3: PFS as determined by BICR
After the target number of 143 PFS events have occurred

PFS will be defined as the time from the date of randomization until the date of progression (as determined by BICR from tumor assessments using RECIST v1.1) or death due to any cause, whichever occurs earlier.

Dose Escalation
6 weeks of RYZ101 treatment

Incidence rate of DLTs during the first 6 weeks of RYZ101 treatment

Endocrine Therapy Combination Dose Escalation
[Time Frame: 6 weeks of study treatment]

Incidence rate of DLTs during the first 6 weeks of study treatment

Endocrine Therapy Combination Dose Escalation and Expansion
Up to approximately 5 years after the last subject has completed RYZ101 treatment

Progression Free Survival, defined as the time between first dose of study treatment and progression or death, as assessed by the investigator per RECIST v1.1 criteria

RP2D
42 days of study treatment

RP2D as determined by incidence rate of DLTs

Safety and tolerability of RYZ101 in combination with SoC
Up to 50 months

Safety and tolerability of RYZ101 in combination with SoC as measured by incidence and severity of AEs including SAEs, laboratory changes and other safety findings

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Phase 1b - RYZ101EXPERIMENTALPart 1 is an uncontrolled dose de-escalation study to confirm the safety and determine the RP3D of RYZ101 based on Bayesian optimal interval design.
Phase 3 - RYZ101ACTIVE_COMPARATORActinium 225 radiolabeled somatostatin analog (SSA) for injection
Phase 3 - Standard of CareACTIVE_COMPARATORInvestigator's choice of standard of care between everolimus, sunitinib, octreotide, or lanreotide.
Phase 3 - RYZ101, PK/ECG Substudy adhoc subcohortACTIVE_COMPARATORActinium 225 radiolabeled somatostatin analog (SSA) for injection
Monotherapy Dose EscalationEXPERIMENTALEscalating doses of RYZ101 administered intravenously (IV)
Endocrine Therapy Combination Dose Escalation and ExpansionEXPERIMENTALRYZ101 in combination with investigator's choice of standard of care endocrine therapy
RYZ101 + SoCEXPERIMENTAL -

Interventions

NameTypeDescription
RYZ101DRUGRP3D as determined in Phase 1b
EverolimusDRUGEverolimus
SunitinibDRUGSunitinib
OctreotideDRUGHigh-dose octreotide
LanreotideDRUGLanreotide
Standard of Care Endocrine TherapyDRUGInvestigator's choice of endocrine therapy, such as, anastrozole, elacestrant, exemestane, fulvestrant, imlunestrant, letrozole, tamoxifen, or vepdegestrant
RYZ101 Dose Level 1DRUGDose Level 1
RYZ101 Dose Level 2DRUGDose Level 2
RYZ101 Dose Level 3DRUGDose Level 3
RYZ101 Dose Level -1DRUGDose Level -1
AtezolizumabDRUGAtezolizumab
CarboplatinDRUGCarboplatin
EtoposideDRUGEtoposide
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites54

Inclusion: * Histologically proven, Grade 1-2 well differentiated, inoperable, advanced GEP-NETs (Ki67 ≤20%) Eastern Cooperative Oncology Group (ECOG) status 0-2. Ki67% \<20% is not required for the ad hoc subcohort of the PK/ECG substudy. * Progressive, SSTR-PET positive (i.e., Krenning score 3 or...

Countries:United StatesBelgiumBrazilCanadaFranceNetherlandsSouth KoreaSpainPuerto Rico
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 12, 2026NCT06590857lastUpdatePostDate: changed
LOWNov 12, 2026NCT06590857lastUpdatePostDate: changed
MEDIUMNov 10, 2026NCT05477576Status: RECRUITING → ACTIVE_NOT_RECRUITING
HIGHNov 10, 2026NCT05595460Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMNov 10, 2026NCT06590857Status: ACTIVE_NOT_RECRUITING → RECRUITING
MEDIUMNov 10, 2026NCT05477576Status: RECRUITING → ACTIVE_NOT_RECRUITING
HIGHNov 10, 2026NCT05595460Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMNov 10, 2026NCT06590857Status: ACTIVE_NOT_RECRUITING → RECRUITING
MEDIUMNov 10, 2026NCT05477576Status: RECRUITING → ACTIVE_NOT_RECRUITING
HIGHNov 10, 2026NCT05595460Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMNov 10, 2026NCT06590857Status: ACTIVE_NOT_RECRUITING → RECRUITING

Frequently asked questions about RYZ101

What is RYZ101?

RYZ101 is an investigational small-molecule oncology therapy developed by Bristol-Myers Squibb Company (ticker BMY). It is being studied in gastroenteropancreatic neuroendocrine tumors, metastatic breast cancer, and extensive-stage small cell lung cancer. RYZ101 has received an Orphan Drug designation from the FDA and is in Phase 3 clinical development.

What is RYZ101 used for in GEP-NET?

RYZ101 is being studied in gastroenteropancreatic neuroendocrine tumors that are SSTR-positive, well differentiated, and have progressed following 177Lu-SSA therapy. The Phase 3 trial compares RYZ101 with standard of care in adults with inoperable disease. RYZ101 is investigational and has not been established as a treatment for GEP-NET.

Who makes RYZ101?

RYZ101 is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. Bristol-Myers Squibb is the sponsor of the clinical program evaluating RYZ101 across gastroenteropancreatic neuroendocrine tumors, metastatic breast cancer, and extensive-stage small cell lung cancer.

What phase is RYZ101 in?

RYZ101 is in Phase 3 clinical development. The Phase 3 trial, NCT05477576, is an active-controlled study in SSTR-positive well-differentiated GEP-NET that has progressed after 177Lu-SSA therapy, with enrollment of 343 participants. RYZ101 is investigational and is not approved by the FDA.

What clinical trials is RYZ101 in?

RYZ101 is being evaluated in three registered trials. NCT05477576 is a Phase 3 active-controlled study in GEP-NET. NCT06590857 is a Phase 1/Phase 2 trial in ER-positive, HER2-negative metastatic breast cancer expressing SSTRs. NCT05595460 is a Phase 1 study of RYZ101 combined with standard of care in SSTR-positive extensive-stage small cell lung cancer.

Is RYZ101 the same as RYZ101 Dose Level 1?

RYZ101 Dose Level 1 refers to a dose level of RYZ101, the investigational therapy developed by Bristol-Myers Squibb (BMY). RYZ101 is the drug name, and Dose Level 1 designates a specific dose studied within its clinical program. Both terms refer to the same agent.